How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort.
作者信息
Fotopoulou Christina
机构信息
Department of Surgery and Cancer, Imperial College London, West London Gynecological Cancer Center, Imperial College Healthcare NHS Trust, London, UK.
出版信息
J Gynecol Oncol. 2020 Jan;31(1):e26. doi: 10.3802/jgo.2020.31.e26. Epub 2019 Nov 1.
Abstract
摘要
相似文献
1
How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort.如何预测晚期上皮性卵巢癌体弱患者的治疗失败：个性化手术努力的策略
J Gynecol Oncol. 2020 Jan;31(1):e26. doi: 10.3802/jgo.2020.31.e26. Epub 2019 Nov 1.
2
The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.微创间歇性肿瘤减灭术在晚期上皮性卵巢癌中的作用
Expert Rev Anticancer Ther. 2016 Sep;16(9):899-901. doi: 10.1080/14737140.2016.1219658. Epub 2016 Aug 9.
3
CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.CA125 动力学参数可预测新辅助化疗治疗晚期上皮性卵巢癌患者的最佳减瘤效果。
Gynecol Oncol. 2014 Dec;135(3):542-6. doi: 10.1016/j.ygyno.2014.09.005. Epub 2014 Sep 16.
4
Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.新辅助化疗可提高晚期上皮性卵巢癌的R0细胞减灭率，但不能改善最终结局。
Ann Surg Oncol. 2017 May;24(5):1330-1335. doi: 10.1245/s10434-016-5704-3. Epub 2016 Dec 19.
5
Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits?
Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):585-587. doi: 10.1111/ajo.12737.
6
Surgery for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的手术治疗
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:71-87. doi: 10.1016/j.bpobgyn.2016.10.007. Epub 2016 Oct 20.
7
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply.复发性卵巢癌的二次手术细胞减灭术。回复
N Engl J Med. 2020 Feb 13;382(7):686. doi: 10.1056/NEJMc1916477.
8
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.上皮性卵巢癌间隔性肿瘤细胞减灭术的最佳减瘤预测评分：两中心经验。
J Ovarian Res. 2018 May 30;11(1):42. doi: 10.1186/s13048-018-0415-y.
9
Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.新辅助化疗对晚期上皮性卵巢癌肠切除率的影响
Anticancer Res. 2016 Sep;36(9):4865-71. doi: 10.21873/anticanres.11050.
10
Neoadjuvant chemotherapy fails to improve survival in advanced ovarian cancer: but is it the real culprit?新辅助化疗未能提高晚期卵巢癌患者的生存率：但它真的是罪魁祸首吗？
Int J Gynecol Cancer. 2011 May;21(4):596. doi: 10.1097/IGC.0b013e318214d4af.
引用本文的文献
1
Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer.验证三种预测模型在晚期卵巢癌中不完全减瘤手术的效果。
Sci Rep. 2021 Apr 14;11(1):8111. doi: 10.1038/s41598-021-86928-2.
本文引用的文献
1
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.未接受间隔肿瘤细胞减灭术的新辅助化疗卵巢癌患者的特征和生存情况。
J Gynecol Oncol. 2020 Jan;31(1):e17. doi: 10.3802/jgo.2020.31.e17.
2
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).信任：晚期卵巢癌激进 upfront 外科治疗试验（ENGOT ov33/AGO-OVAR OP7）。
Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331. doi: 10.1136/ijgc-2019-000682. Epub 2019 Aug 15.
3
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.高肿瘤负荷的卵巢癌患者的最大努力细胞减灭术：实践中的差异及其对结局的影响。
Ann Surg Oncol. 2019 Sep;26(9):2943-2951. doi: 10.1245/s10434-019-07516-3. Epub 2019 Jun 26.
4
Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.新诊断晚期卵巢癌新辅助化疗的价值：欧洲视角
J Clin Oncol. 2017 Feb 20;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9.
5
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.新辅助化疗在卵巢癌治疗中的应用及疗效
J Clin Oncol. 2016 Nov 10;34(32):3854-3863. doi: 10.1200/JCO.2016.68.1239.
6
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.重新思考卵巢癌II：降低高级别浆液性卵巢癌的死亡率
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.
7
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.新诊断的晚期卵巢癌的初次化疗与初次手术（CHORUS）：一项开放标签、随机、对照、非劣效性试验。
Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.
8
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
9
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.铂类时代最大程度肿瘤细胞减灭术对晚期卵巢癌的生存影响：一项荟萃分析。
J Clin Oncol. 2002 Mar 1;20(5):1248-59. doi: 10.1200/JCO.2002.20.5.1248.
Zotero 插件